Float Short %

4.54

Margin Of Safety %

Put/Call OI Ratio

1.51

EPS Next Q Diff

-0.2

EPS Last/This Y

3.52

EPS This/Next Y

2.22

Price

137.33

Target Price

179.63

Analyst Recom

1.4

Performance Q

-3.7

Relative Volume

0.74

Beta

0.32

Ticker: NBIX

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	NBIX	145.22	1.63	0.59	8365
2025-12-29	NBIX	143.6	1.63	5.50	8387
2025-12-30	NBIX	140.91	1.63	7.25	8393
2025-12-31	NBIX	141.81	1.65	0.11	8439
2026-01-02	NBIX	140.08	1.63	0.31	8488
2026-01-05	NBIX	135.96	1.62	0.02	8500
2026-01-06	NBIX	137.31	1.44	0.24	8918
2026-01-07	NBIX	140.55	1.43	0.08	8930
2026-01-08	NBIX	135.54	1.32	3.79	9233
2026-01-09	NBIX	135.79	1.33	0.20	9311
2026-01-12	NBIX	132.66	1.28	0.52	9558
2026-01-13	NBIX	132.23	1.24	0.09	9550
2026-01-14	NBIX	135.37	1.27	0.48	9795
2026-01-15	NBIX	133.33	1.27	263.70	9815
2026-01-16	NBIX	132.38	1.22	1.90	9622
2026-01-20	NBIX	134.51	1.52	0.06	8744
2026-01-21	NBIX	135.47	1.50	28.25	8802
2026-01-22	NBIX	137.37	1.51	3.50	8847
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	NBIX	145.21	42.4	471.8	6.92
2025-12-29	NBIX	143.57	42.4	472.0	6.92
2025-12-30	NBIX	140.94	42.4	463.8	6.92
2025-12-31	NBIX	141.87	42.4	492.3	6.92
2026-01-02	NBIX	140.62	42.4	475.4	6.92
2026-01-05	NBIX	135.91	42.4	447.5	6.92
2026-01-06	NBIX	137.32	42.4	496.2	6.92
2026-01-07	NBIX	140.61	42.4	511.6	6.92
2026-01-08	NBIX	135.57	42.4	444.6	6.92
2026-01-09	NBIX	135.76	42.4	486.6	6.92
2026-01-12	NBIX	132.65	42.4	459.0	6.92
2026-01-13	NBIX	132.24	42.4	481.3	6.92
2026-01-14	NBIX	135.36	41.3	511.4	6.92
2026-01-15	NBIX	133.30	41.3	468.1	6.92
2026-01-16	NBIX	132.40	41.3	476.9	6.92
2026-01-20	NBIX	134.55	41.3	503.4	6.92
2026-01-21	NBIX	135.47	41.3	493.1	6.92
2026-01-22	NBIX	137.33	41.3	501.0	6.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	NBIX	-8.70	-1.30	4.06
2025-12-29	NBIX	-8.70	-1.30	4.06
2025-12-30	NBIX	-8.70	-1.30	4.06
2025-12-31	NBIX	-8.70	-1.30	4.06
2026-01-02	NBIX	-8.70	-1.30	4.06
2026-01-05	NBIX	-8.70	-1.30	4.06
2026-01-06	NBIX	-8.70	-1.30	4.06
2026-01-07	NBIX	-8.70	-1.30	4.06
2026-01-08	NBIX	-8.05	-1.30	4.06
2026-01-09	NBIX	-8.05	-1.30	4.06
2026-01-12	NBIX	-6.08	-1.31	4.06
2026-01-13	NBIX	-6.08	-1.31	4.19
2026-01-14	NBIX	-6.08	-1.31	4.19
2026-01-15	NBIX	-6.08	-1.31	4.19
2026-01-16	NBIX	-6.08	-1.31	4.19
2026-01-20	NBIX	-6.08	-0.96	4.19
2026-01-21	NBIX	-7.28	-0.96	4.19
2026-01-22	NBIX	-7.28	-0.96	4.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

2.17

Avg. EPS Est. Current Quarter

2.41

Avg. EPS Est. Next Quarter

1.97

Insider Transactions

-7.28

Institutional Transactions

-0.96

Beta

0.32

Average Sales Estimate Current Quarter

803

Average Sales Estimate Next Quarter

778

Fair Value

152.49

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.3

Max Drawdown 5-Year %

-42.9

Target Price

179.63

P/E

32.81

Forward P/E

19.39

PEG

0.54

P/S

5.11

P/B

4.56

P/Free Cash Flow

23.09

EPS

4.19

Average EPS Est. Cur. Y

6.92

EPS Next Y. (Est.)

9.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.95

Relative Volume

0.74

Return on Equity vs Sector %

-13

Return on Equity vs Industry %

7.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

501

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y